129488-74-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-cyanopropan-2-yl)benzoic acid is used as an intermediate in the synthesis of various organic compounds for the production of pharmaceuticals. Its unique structure and properties make it a valuable component in the development of new drugs.
Used in Drug Development:
4-(2-cyanopropan-2-yl)benzoic acid is being studied for its potential medicinal properties and is being researched for its potential applications in the field of drug development. Its specific characteristics may contribute to the discovery of new therapeutic agents.

Upstream product

• 129488-73-9 methyl 4-(1-cyano-1-methylethyl)-benzoate 
• 76469-88-0 methyl 4-(cyanomethyl)benzoate 
• 74-88-4 methyl iodide 
• 1309580-85-5 ethyl 4-(1-cyano-1-methyl-ethyl)benzoate 
• 101184-73-0 2-(4-bromophenyl)-2-methylpropanenitrile 
• 40119-34-4 2-methyl-2-(4-methylphenyl)propionitrile 

Downstream Products

• 1147531-81-4 C₂₄H₂₉BN₂O₃ 
• 1366047-63-3 2-(4-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenyl)-2-methylpropanenitrile 
• 1190705-75-9 2-(4-(8-bromo-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl) phenyl)-2-methylpropanenitrile 
• 1442120-92-4 2-({1-[4-(1-cyano-1-methylethyl)benzoyl]piperidin-4-yl}methyl)-N-(2-methoxyethyl)-4-methyl-2H-indazole-5-carboxamide 
• 1146695-65-9 2-(4-formylphenyl)-2-methylpropanenitrile 
• 1201645-56-8 N-(5-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridine-3-yl)benzenesulfonamide 
• 1201645-37-5 N-(5-(3-acetyl-1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-2-yl)acetamide 
• 1201645-08-0 2-methyl-2-(4-(8-(3-(4-methylpiperazin-1-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)propanenitrile 
• 1201645-49-9 N-(3-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)phenyl)benzamide 
• 1201645-42-2 2-(4-(8-(9H-carbazol-2-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201645-75-1 2-(4-(3-acetyl-8-(4-methylsulfonylpiperazin-1-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201645-41-1 2-(4-(3-acetyl-8-(6-phenoxypyridin-3-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201644-55-4 tert-butyl 5-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-3-ylcarbamate 
• 1286756-81-7 C₃₁H₃₁N₅O₂ 

Relevant academic research and scientific papers

OXADIAZOLES AS FUNGICIDES

The present invention relates to novel oxadiazoles of Formula (I) wherein, R1, L1, A1, A2, A3, A4, L2 and R2 are as defined in the detailed description. The present in

VEGFR-2 inhibitor and preparation method thereof

The invention provides a compound I used as a VEGFR-2 inhibitor, a preparation method thereof, and an application of the compound I in the preparation of medicines for treating persistent vasculature induced diseases.

SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS

The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Provided are compounds according to Formula (I), or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6 , R7, and R8 are as defined, which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PB -kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.

CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted cyclylamine derivatives as shown in formulas (1).